New Treatments & Clinical Trials for Ewing Sarcoma

Ewing sarcoma is an aggressive bone and soft tissue cancer most common in children, adolescents, and young adults, caused by a characteristic chromosomal translocation that creates the EWSR1-FLI1 fusion oncogene. Localized disease can often be cured with intensive multiagent chemotherapy plus surgery or radiation, but metastatic and relapsed disease has a very poor prognosis with few effective options.

What's actually going on in research

Standard treatment for localized Ewing sarcoma combines chemotherapy with local control through surgery, radiation, or both, achieving cure in roughly 70–80% of localized cases. Metastatic disease and relapse represent the major unmet need; trials are testing PARP inhibitors, immune checkpoint inhibitors, antibody-drug conjugates targeting GD2, and T cell-engaging immunotherapies. The EWS-FLI1 fusion protein itself is now being targeted directly by novel small molecules.

What to know before you search

Eligibility depends on whether disease is localized or metastatic, prior chemotherapy received, age, and the specific EWS translocation variant.

What types of trials are currently open

• EWS-FLI1 targeted trials — Testing small molecules that directly inhibit the defining fusion oncogene driving Ewing sarcoma.
• GD2-targeted immunotherapy trials — Evaluating antibody-drug conjugates and bispecifics targeting the GD2 surface antigen.
• PARP inhibitor trials — Studying PARP inhibitors alone or with chemotherapy to exploit DNA repair vulnerabilities.
• Immune checkpoint inhibitor trials — Testing PD-1/PD-L1 and CTLA-4 blocking antibodies in metastatic and relapsed Ewing sarcoma.
• Intensification trials — Evaluating high-dose chemotherapy with stem cell rescue and novel induction regimens for high-risk localized disease.